Accelerating Product Excellence in Innovation and for Clinical Adoption (APEx) (U24 Clinical Trial Not Allowed)

Summary

The National Institutes of Health (NIH) is soliciting applications under the APEx program (RFA-DE-27-002), a U24 cooperative agreement mechanism focused on accelerating product excellence in innovation and clinical adoption. This is a federal grant opportunity posted on Grants.gov. Clinical trials are explicitly not allowed under this funding opportunity. The program appears aimed at supporting research infrastructure or resource development to advance the translation of innovations toward clinical use.

What they want

How they evaluate

Risks & flags

• Synopsis contains minimal detail — full programmatic requirements, budget limits, and eligibility criteria are not disclosed in the posted text, limiting competitive assessment
• Agency code 'HHS-NIH11' suggests this may be issued by a specific NIH institute (likely NIDCR given the 'DE' prefix in RFA-DE-27-002), narrowing the eligible applicant pool by subject matter expertise